Company

AstriVax Therapeutics

Biotechnology Research Heverlee, Vlaams Brabant, Be 36 employees

Employees: 36
Contacts: 3
Emails: 3

astrivax.com LinkedIn Crunchbase

AstriVax Therapeutics Overview

Headquarters: Heverlee, Vlaams Brabant, Be
Website: astrivax.com
Industry: Biotechnology Research
Employees: 36
Funding: 3.2M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

to drive our mission forward

About AstriVax Therapeutics

AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.

AstriVax Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 3
Email contacts: 3; 75.0% coverage

AstriVax Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Johan Neyts	Professor of Virology, Ku Leuven	Leuven, Flemish Region, Belgium	Email
Mathieu Peeters	Chief Development Officer at Astrivax	Overijse, Flemish Region, Belgium	Email
Frederik Stevenaert	Head Translational Immunology Astrivax	Oudenaarde, Flemish Region, Belgium	Email
Jan Eelen	Passionate About Operational Excellence		View